126 results on '"Lakhani N"'
Search Results
2. Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer
3. 44O Updated results from a phase I study evaluating the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC
4. 150P Phase I study of fianlimab: A human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel) - Subgroup analysis
5. 196TiP A phase I study of REGN6569, a GITR monoclonal antibody (mAb), in combination with cemiplimab in patients with advanced solid tumour malignancies
6. 172P Phase I study of JTX-8064, a LILRB2 (ILT4) inhibitor, as monotherapy and combination with pimivalimab (pimi), a PD-1 inhibitor (PD-1i), in patients (pts) with advanced solid tumors
7. 400P Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)
8. Efficacy signals, long-term exposure and safety data from a phase 1–2 study of a cell-penetrating peptide antagonist of CEBPβ, a novel target, in patients (pts) with refractory solid tumors
9. Establishment and characterization of a panel of BRAFV600E colorectal XPDX models from patients with acquired resistance to targeted therapies
10. Identification and molecular characterization of invasive lobular breast cancer models in a panel of 180 breast XPDX models
11. Thalassaemia among Asians in Britain
12. SO-31 ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer
13. 660MO First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase I study (SGNB7H4V-001)
14. 663P Safety and preliminary efficacy of the KRAS G12C Inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC
15. Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors
16. P01.06 CX-2029, a Probody Drug Conjugate Targeting CD71 in Patients With Selected Tumor Types: PROCLAIM-CX-2029 Dose Expansion Phase
17. 1019O Phase I studies of Sym021, an anti-PD-1 antibody, alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
18. A cellular and molecular investigation of the action of PMX464, a putative thioredoxin inhibitor, in normal and colorectal cancer cell lines
19. 38 (PB028) - Establishment and characterization of a panel of BRAFV600E colorectal XPDX models from patients with acquired resistance to targeted therapies
20. 337 (PB117) - Identification and molecular characterization of invasive lobular breast cancer models in a panel of 180 breast XPDX models
21. 230 (PB110) - Efficacy signals, long-term exposure and safety data from a phase 1–2 study of a cell-penetrating peptide antagonist of CEBPβ, a novel target, in patients (pts) with refractory solid tumors
22. Phase I dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumours: Updated results
23. A phase I study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
24. Preliminary results of pamiparib (BGB-290), a PARP1/2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumors
25. Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292
26. A Phase 1a/2a trial of AVID100, an anti-EGFR antibody-drug conjugate
27. Technology-Enabled Remote Monitoring and Self-Management — Vision for Patient Empowerment Following Cardiac and Vascular Surgery: User Testing and Randomized Controlled Trial Protocol
28. OA 12.07 LOXO-292, a Potent, Highly Selective RET Inhibitor, in MKI-Resistant RET Fusion-Positive Lung Cancer Patients with and without Brain Metastases
29. A Phase 1 PK/PD Study of ASN003, a novel highly selective BRAF and PI3K inhibitor, in patients with advanced solid tumors
30. 1196P - Phase I dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumours: Updated results
31. 1197P - A phase I study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
32. PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers
33. Pharmacokinetics (PK) of CRLX101 administered weekly in patients (pts) with advanced solid tumors
34. Evaluation of weekly dosing of CRLX101 alone and in combination with bevacizumab (bev) in patients (pts) with advanced solid tumors
35. ANG1005, a novel peptide-paclitaxel conjugate crosses the BBB and shows activity in patients with recurrent CNS metastasis from breast cancer, results from a phase II clinical study
36. 421P - Preliminary results of pamiparib (BGB-290), a PARP1/2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumors
37. 105P - Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292
38. 46O - A Phase 1a/2a trial of AVID100, an anti-EGFR antibody-drug conjugate
39. 371PD - A Phase 1 PK/PD Study of ASN003, a novel highly selective BRAF and PI3K inhibitor, in patients with advanced solid tumors
40. 393P - Evaluation of weekly dosing of CRLX101 alone and in combination with bevacizumab (bev) in patients (pts) with advanced solid tumors
41. 394P - Pharmacokinetics (PK) of CRLX101 administered weekly in patients (pts) with advanced solid tumors
42. 324O - ANG1005, a novel peptide-paclitaxel conjugate crosses the BBB and shows activity in patients with recurrent CNS metastasis from breast cancer, results from a phase II clinical study
43. A growing abdominal problem
44. The African Vaccine-Preventable Diseases Network: a vaccine advocacy initiative
45. Engineering novel synthetic biological systems
46. Single oral dose pharmacokinetics (PK) and safety of 2-methoxyestradiol (2ME2) in patients with solid tumors
47. Determination of the antiangiogenesis agent 2-methoxyestradiol in human plasma by liquid chromatography with ultraviolet detection
48. Thalassaemia among Asians in Britain
49. Alcohol use amongst community-dwelling elderly people: a review of the literature.
50. Facilitating early discharge: the role of the crisis resolution/home treatment team.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.